alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Clinical trials

Communication Bridge-2 randomized controlled trial: Recruitment and baseline features

Emily Rogalski, Matthew Bona, Marissa Esparza, Aimee Mooney, Melanie Fried-Oken, Alfred Rademaker, Angela Roberts. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024-11-26

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 80 out of 100. Clinical trials

Topic: Health services, long-term care and technology

Ninety-five participant dyads (PPA mean baseline age: 67.1; 48% female) from four countries were enrolled and randomized. Global recruitment, enrollment, and randomization of individuals with PPA into a video chat-delivered non-pharmacologic RCT is feasible. This trial provides a potential model for conducting rigorous non-pharmacologic efficacy trials for Alzheimer's disease and related dementias. HIGHLIGHTS: Primary progressive aphasia (PPA) negatively impacts communication participation. Communication Bridge-2 (CB2) is a telemedicine-delivered randomized controlled trial. CB2 included global recruitment and randomization of 95 PPA participant dyads. CB2, the first international superiority trial for PPA using video chat shows feasibility. The study provides a model for rigorous non-pharmacologic trials for Alzheimer's disease and related dementias.

Key findings

New to this subject? Start with our plain-English guide: Registered clinical trials →

Study details

How this study scored 80/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 45 of the 56 points it could be judged on, which is 80 of 100. Total 80 of 100.45 of the 56 points we could judge = 80 of 100

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 45 of the 56 points we could judge it on, which is 80 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 11 / 12 A randomised controlled trial
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39588869)
Free to read — / 2 Access not recorded — left out of this score
Points 45 / 56 Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 45 of the 56 points we could judge it on is 80 out of 100.
Total 80 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

APA 7th

Rogalski, E., Bona, M., Esparza, M., Mooney, A., Fried-Oken, M., Rademaker, A., et al. (2025). Communication Bridge-2 randomized controlled trial: Recruitment and baseline features. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.14168

Vancouver

Rogalski E, Bona M, Esparza M, Mooney A, Fried-Oken M, Rademaker A, et al. Communication Bridge-2 randomized controlled trial: Recruitment and baseline features. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.14168. PMID: 39588869.

BibTeX

@article{rogalski2025-39588869,
  author  = {Rogalski, Emily and Bona, Matthew and Esparza, Marissa and Mooney, Aimee and Fried-Oken, Melanie and Rademaker, Alfred and Roberts, Angela},
  title   = {{Communication Bridge-2 randomized controlled trial: Recruitment and baseline features}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2025},
  doi     = {10.1002/alz.14168},
  pmid    = {39588869},
  url     = {https://doi.org/10.1002/alz.14168}
}

Related studies in Clinical trials

Also tagged “computerized”

238 studies in the library carry the topic tag “computerized”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 238 tagged studies.

Similar studies

More on Clinical trials

See all studies in Clinical trials →